# Axcella Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/axcella-health

- Industry: Food
- Headquarters: Cambridge, US
- Website: www.axcellahealth.com
- Total disclosed funding: $121M
- Latest round: Series E (Nov 1, 2018)
- Investors on record: 4

## About

Axcella Health, Inc. is a biotechnology company focused on developing Endogenous Metabolic Modulators to address metabolic dysregulation through innovative therapeutic solutions.Founded in 2010, Axcella Health, Inc. is headquartered in Cambridge, US. The company specializes in the development of Endogenous Metabolic Modulators, particularly targeting metabolic disorders. Geoffrey Maltzahn is the founder of the firm, which has successfully raised USD 71.00 mn through an IPO on May 8, 2019, marking its strategic evolution in the biopharmaceutical sector. The company has engaged in 7 deals throughout its operational history.Axcella Health, Inc. specializes in the development of Endogenous Metabolic Modulators (EMMs), a diverse class of molecules that play a critical role in regulating human metabolism. The company’s main product offerings include AXA candidates, with the lead candidate being AXA1665, which is being developed as a therapeutic drug for hepatic encephalopathy (HE). Axcella's development platform focuses on translating complex human biology into both drug and non-drug candidates that aim to address metabolic dysregulation, a condition central to many health issues. These offerings target various applications in the liver, muscle, and blood systems. Axcella’s products are primarily aimed at healthcare providers and institutions involved in the treatment of metabolic disorders, with a focus on markets across North America and Europe.Axcella Health, Inc. operates primarily through partnerships and collaborations in the biopharmaceutical sector, focusing on clinical studies aimed at evaluating the safety and efficacy of its AXA candidates. The firm reported an EBITDA of -USD 76.58 mn for the year 2022. Revenue generation is structured around transactions including research grants, development partnerships with pharmaceutical companies, and potential future sales of approved drug products. As a clinical-stage biotechnology firm, Axcella may also explore revenue avenues through licensing agreements, particularly once its candidates receive regulatory approval.Axcella Health, Inc. aims to enhance its product portfolio by continuing to develop its lead AXA candidate, AXA1665, with plans to advance clinical trials in the coming years. The company’s recent IPO in May 2019 raised USD 71.00 mn, which will be utilized to fund ongoing research and development initiatives, including the expansion of its clinical trials and exploration of new markets in Europe and Asia by 2024. Axcella is committed to establishing strategic partnerships to boost market penetration and facilitate the introduction of approved products into wider healthcare settings.

## Funding rounds

- Series E, Nov 1, 2018, $59M — Flagship Pioneering, Fidelity Investments, Nestle Health Science SA, Gurnet Point Capital
- Series C, May 28, 2015, $11M — Flagship Pioneering, Fidelity Investments
- Series C, Jan 30, 2015, $28M — Flagship Pioneering
- Series B, Feb 13, 2014, $12M — Flagship Pioneering
- Series A, Apr 8, 2011, $11M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C, Series E
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C, Series E
- Nestle Health Science SA — Series E
- Gurnet Point Capital (https://capitalatlas.ai/funds/gurnet-point-capital) — Series E